Cyclacel Pharmaceuticals (NASDAQ:CYCC) is set to post its quarterly earnings results after the market closes on Tuesday, May 14th. Analysts expect Cyclacel Pharmaceuticals to post earnings of ($0.19) per share for the quarter.
Cyclacel Pharmaceuticals (NASDAQ:CYCC) last announced its quarterly earnings data on Wednesday, March 27th. The biotechnology company reported ($0.17) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.17). The business had revenue of $0.15 million during the quarter. On average, analysts expect Cyclacel Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of CYCC traded up $0.02 during mid-day trading on Thursday, reaching $0.74. The company’s stock had a trading volume of 140,297 shares, compared to its average volume of 569,374. The firm has a market cap of $12.47 million, a price-to-earnings ratio of -1.19 and a beta of 3.36. Cyclacel Pharmaceuticals has a 52 week low of $0.51 and a 52 week high of $1.87.
Separately, Zacks Investment Research downgraded shares of Cyclacel Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, April 3rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. Cyclacel Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $5.63.
WARNING: This story was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2019/05/09/cyclacel-pharmaceuticals-cycc-to-release-earnings-on-tuesday.html.
Cyclacel Pharmaceuticals Company Profile
Cyclacel Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes.
Featured Article: How to Profit and Limit Losses With Stop Orders
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.